149428-73-9

Basic information

• Product Name: 4-Methoxy-3-(phenethyloxy)benzaldehyde
• Synonyms: 4-Methoxy-3-(phenethyloxy)benzaldehyde
• CAS NO: 149428-73-9
• Molecular Formula: C₁₆H₁₆O₃
• Molecular Weight: 256.299
• Mol File: 149428-73-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Methoxy-3-(phenethyloxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-3-(phenethyloxy)benzaldehyde(149428-73-9)
• EPA Substance Registry System: 4-Methoxy-3-(phenethyloxy)benzaldehyde(149428-73-9)

Safety Data

• Hazardous Substances Data: 149428-73-9(Hazardous Substances Data)

Upstream product

• 621-59-0 isovanillin 
• 103-63-9 1-phenyl-2-bromoethane 
• 60-12-8 2-phenylethanol 
• 1972-28-7 diethylazodicarboxylate 
• 603-35-0 triphenylphosphine 

Downstream Products

• 1026804-30-7 2-(4-methoxy-3-phenethyloxy-phenyl)-1-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethanone 
• 1026596-08-6 3-(4-methoxy-3-phenethyloxy-phenyl)-N,N-dipropyl-propionamide 
• 1026015-00-8 2-(4-methoxy-3-phenethyloxy-phenyl)-1-morpholin-4-yl-ethanone 
• 1026321-04-9 2-(4-methoxy-3-phenethyloxy-phenyl)-1-pyrrolidin-1-yl-ethanone 
• 1026199-83-6 3-(4-methoxy-3-phenethyloxy-phenyl)-propionic acid ethyl ester 
• 149429-06-1 3-[4-Methoxy-3-(2-phenylethoxy)phenyl]propionic acid 
• 149428-91-1 4-methoxy-3-(2-phenylethoxy)phenylacetic acid 
• 220718-66-1 4-methoxy-3-(2-phenylethoxy)phenylacetonitrile 

Relevant articles and documents

Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells

Insulin resistance is a complex altered metabolic condition characterized by impaired insulin signaling and implicated in the pathogenesis of serious human diseases, such as diabetes, obesity, neurodegenerative pathologies. In pursuing our aim to identify new agents able to improve cellular insulin sensitivity, we have synthesized new 4-[(5-arylidene-4-oxo-2-phenylimino/ oxothiazolidin-3-yl)methyl]benzoic acids (5, 8) and evaluated their inhibitory activity towards human protein tyrosine phosphatases PTP1B, LMW-PTP and TCPTP, enzymes which are involved in the development of insulin resistance. Compounds 5 and 8 showed from moderate to significant selectivity toward PTP1B over both the highly homologous TCPTP and the two isoforms of human LMW-PTP. In addition, most of the tested compounds selectively inhibited LMW-PTP IF1 over the isoform IF2. Docking studies into the active sites of PTP1B and LMW-PTP aided the rationalization of the observed PTP inhibitory profile. Moreover, most tested compounds were capable to induce the insulin metabolic pathway in mouse C2C12 skeletal muscle cells by remarkably stimulating both IRβ phosphorylation and 2-deoxyglucose cellular uptake.

Use of 2-phenylmorpholin-5-one derivatives

A 2-phenylmorpholin-5-one derivative having the formula (I): wherein R1 represents a C1 to C8 alkyl group, a C3 to C7 cycloalkyl group or an indanyl group, R2 represents a C1 to C4 alkyl group, R3 represents a hydrogen atom, a C1 to C5 alkyl group, etc., R4 represents a hydrogen atom, a C1 to C6 alkyl group, etc., R5, R6 represent a hydrogen atom, a C1 to C5 alkyl group, etc.,an optical isomer thereof or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof and a pharmaceutical composition containing the same.The above compound has a strong type IV phosphodiesterase (PDE) inhibitory activity and has bronchodilater and antiinflammatory effects.

5-phenyl-3-pyridazinone derivatives and drug composition containing the same

A 5-phenyl-3-pyridazinone derivative having the formula (I) wherein R1represents an unsubstituted or substituted C1to C8alkyl group, C3to C7cycloalkyl group, or indanyl group; R2represents